Patients with retinitis pigmentosa experienced vision gains at weeks 52 and maintained those gains through 4 years, according to a study presented at the American Academy of Ophthalmology meeting. The study explored the one-time injection of MCO-010 (Mogenry, Nanoscope Therapeutics) in patients with low vision from retinitis pigmentosa, with 40% of patients in the MCO-010 groups gaining more than 0.3 logMAR of vision, or about three lines of ETDRS, which was statistically significant. According to Kenneth C. Fan, MD, MBA, of Retina Consultants of Texas, MCO-010 was safe and well tolerated by patients through 4 years of follow-up. Some patients experienced mild intraocular inflammation that was transient and treatable. There were no serious adverse events.
Patients maintained their vision gains through week 204 of the study, known as REMAIN, which is the long-term extension study of the phase 2b/3 RESTORE trial. The RESTORE trial included 27 patients split into three groups: low-dose MCO-010 (0.9E11 gc/eye), high-dose MCO-010 (1.2E11 gc/eye), and sham injection. Fan noted that retinitis pigmentosa causes slow, progressive vision loss over time, often leaving patients legally blind in their 30s and 40s, making it a tragic disease with no current treatment. “Optogenetics is a huge future potential for patients with low vision and irreversible vision loss,” Fan said. REMAIN and RESTORE demonstrated positive data in optogenetics for patients with irreversible low-vision retinitis pigmentosa.
